Opthea Ltd
NASDAQ:OPT
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
O
|
Opthea Ltd
NASDAQ:OPT
|
AU |
|
C
|
Centene Corp
F:QEN
|
US |
|
L
|
Lloyds Banking Group PLC
XETRA:LLD
|
UK |
|
T
|
TUI AG
XHAM:TUI1
|
DE |
Opthea Ltd
Opthea Ltd is a biotechnology company that develops eye-disease medicines, with its main focus on treatments for retinal diseases such as wet age-related macular degeneration and diabetic macular edema. Its lead drug candidate is an injected therapy designed to stop abnormal blood vessel growth and fluid leakage in the eye, which are major causes of vision loss. The company does not sell a finished consumer product. Instead, it builds drug candidates, runs clinical trials, and works toward approval so its medicine can be licensed to, or sold through, larger pharmaceutical companies that already have sales and distribution reach in eye care. Its customers are therefore mostly drug partners, regulators, doctors, and, ultimately, the patients who receive the treatment. Opthea makes money mainly through financing, partnerships, and any future licensing or commercial payments tied to its drug program. What makes its business model different is that it is a focused drug developer rather than a broad pharmaceutical company: its value depends on whether one or a few eye medicines can prove effective and become part of standard retina care.
Opthea Ltd is a biotechnology company that develops eye-disease medicines, with its main focus on treatments for retinal diseases such as wet age-related macular degeneration and diabetic macular edema. Its lead drug candidate is an injected therapy designed to stop abnormal blood vessel growth and fluid leakage in the eye, which are major causes of vision loss.
The company does not sell a finished consumer product. Instead, it builds drug candidates, runs clinical trials, and works toward approval so its medicine can be licensed to, or sold through, larger pharmaceutical companies that already have sales and distribution reach in eye care. Its customers are therefore mostly drug partners, regulators, doctors, and, ultimately, the patients who receive the treatment.
Opthea makes money mainly through financing, partnerships, and any future licensing or commercial payments tied to its drug program. What makes its business model different is that it is a focused drug developer rather than a broad pharmaceutical company: its value depends on whether one or a few eye medicines can prove effective and become part of standard retina care.
